Letter: Not so double-blind?

Clinical Trial

T W Anderson et al. Br Med J. 1976.

. 1976 Feb 21;1(6007):457-8.

doi: 10.1136/bmj.1.6007.457-d.

No abstract available

Similar articles

A consideration of the guidelines for investigating potential new drugs in humans in the United Kingdom.
McGillion FB. McGillion FB. Methods Find Exp Clin Pharmacol. 1979 Apr;1(1):45-50. Methods Find Exp Clin Pharmacol. 1979. PMID: 552581 No abstract available.
Pharmaceutical development and specification of stereoisomers.
Williams RC, Riley CM, Sigvardson KW, Fortunak J, Ma P, Nicolas EC, Unger SE, Krahn DF, Bremner SL. Williams RC, et al. J Pharm Biomed Anal. 1998 Sep 1;17(6-7):917-24. doi: 10.1016/s0731-7085(98)00059-4. J Pharm Biomed Anal. 1998. PMID: 9884183 Review.
Effectiveness/efficacy difference too often ignored.
Silverman E. Silverman E. Manag Care. 2013 Jan;22(1):36. Manag Care. 2013. PMID: 23373138 No abstract available.
Letter: Not so double-blind?
[No authors listed] [No authors listed] Br Med J. 1976 Mar 20;1(6011):710. Br Med J. 1976. PMID: 766910 Free PMC article. Clinical Trial. No abstract available.
Improvement of phase III psychotropic drug trials by intensive phase II work.
Klein DF. Klein DF. Neuropsychopharmacology. 1991 Jun;4(4):251-8; discussion 259-71. Neuropsychopharmacology. 1991. PMID: 1867735 Review.

Assessing clinical trials--first steps.
Gore SM. Gore SM. Br Med J (Clin Res Ed). 1981 May 16;282(6276):1605-7. doi: 10.1136/bmj.282.6276.1605. Br Med J (Clin Res Ed). 1981. PMID: 6786582 Free PMC article. No abstract available.
Assessing clinical trials- double-blind trials.
Gore SM. Gore SM. Br Med J (Clin Res Ed). 1981 Jul 11;283(6284):122-4. doi: 10.1136/bmj.283.6284.122. Br Med J (Clin Res Ed). 1981. PMID: 6789934 Free PMC article. No abstract available.